New Studies | Surviving Mesothelioma

Novel Chemotherapy Technique Appears to Boost Mesothelioma Survival

German surgeons are reporting on a potential new way to improve outcomes for people with malignant pleural mesothelioma by infusing chemotherapy drugs in an isolated area and then removing them. In an article in OncoTargets and Therapy, surgical oncologists from Burghausen, Germany say they were prompted to test the new technique after radical mesothelioma surgery “failed to translate into a definite survival advantage.” Mesothelioma Treatment Risks Although … Continue reading Novel Chemotherapy Technique Appears to Boost Mesothelioma Survival »

Long-Term Peritoneal Mesothelioma Survival with Apitolisib

There is hopeful news this week about the survivability of peritoneal mesothelioma, particularly when relapses are treated with a powerful drug called apitolisib. Peritoneal mesothelioma is a less common form of the rare asbestos-related cancer, malignant mesothelioma. It starts on the membrane that surround the abdominal organs and can quickly spread throughout the abdomen. According to the National Cancer Institute, the one-year survival rates for … Continue reading Long-Term Peritoneal Mesothelioma Survival with Apitolisib »

Radiotherapy for Lymphoma as a Risk Factor for Malignant Mesothelioma

People who received radiotherapy for the treatment of lymphoma have a higher chance of developing malignant mesothelioma later in life. That is the conclusion of a large, population-based study of American lymphoma patients over four decades. A Closer Look at the Data Using data from the US Surveillance, Epidemiology, and End Results (SEER) database, researchers at Stanford Cancer Center and scientific consulting firm Exponent, Inc. … Continue reading Radiotherapy for Lymphoma as a Risk Factor for Malignant Mesothelioma »

Antibody-Drug Conjugate Fails to Stop Recurrent Pleural Mesothelioma

A new drug designed to treat recurrent malignant mesothelioma while minimizing side effects has failed to meet expectations. Anetumab ravtansine, is an antibody-drug conjugate (ADC) developed with biotechnology firms ImmunoGen and MorphoSys and owned by Bayer.  It had been the focus of a Phase II clinical trial for pleural mesothelioma. The trial has now been stopped. Understanding ADCs Many of the most dangerous side effects of … Continue reading Antibody-Drug Conjugate Fails to Stop Recurrent Pleural Mesothelioma »

Second-Line Immunotherapy Treatment Fails to Improve Mesothelioma Survival

A large international clinical trial of the immunotherapy drug tremelimumab as a second- or third-line treatment option for malignant mesothelioma has produced some disappointing news. Drug maker AstraZeneca has just released an update on the ongoing DETERMINE trial which suggests that the survival rates are roughly the same for previously-treated mesothelioma patients whether they later received treatment with tremelimumab or a placebo. What is Tremelimumab? … Continue reading Second-Line Immunotherapy Treatment Fails to Improve Mesothelioma Survival »

High Dose Radiotherapy Not Recommended for Managing Mesothelioma Symptoms

High dose radiotherapy may work wonders for some kinds of cancer but it is not recommended as a way to manage the symptoms of pleural mesothelioma. That word comes from a group of mesothelioma experts in one of the world’s mesothelioma hot spots – Melbourne, Australia. Australia has the dubious distinction of having one of the highest rates of malignant mesothelioma in the world due to … Continue reading High Dose Radiotherapy Not Recommended for Managing Mesothelioma Symptoms »

IMRT “Feasible and Effective” for Pleural Mesothelioma

When malignant pleural mesothelioma patients receive radiation therapy in the form of IMRT (intensity modulated radiation therapy) at an experienced institution, the treatment can be both feasible and effective. That is the conclusion of Dr. Kenneth Rosenzweig, Chairman of the Department of Radiation Oncology at Mount Sinai School of Medicine in New York. Rosenzweig is the author of a new summary of radiation therapy in … Continue reading IMRT “Feasible and Effective” for Pleural Mesothelioma »

Study to Test New Three-Drug Treatment for Pleural Mesothelioma

The makers of a VEGF-inhibitor called nintedanib are recruiting patients with unresectable pleural mesothelioma for a Phase III clinical trial of the drug in combination with standard chemotherapy. The multicenter trial sponsored by drug maker Boehringer Ingelheim will eventually include a total of 450 mesothelioma patients, but preliminary results from the first 87 patients look promising.  According to data presented at the 2017 American Society of Clinical Oncology … Continue reading Study to Test New Three-Drug Treatment for Pleural Mesothelioma »

Chamomile Tea May Hold the Secret to Longer Mesothelioma Survival

A new study suggests that a flavonoid found in parsley, celery, and chamomile tea may help improve the odds of surviving malignant mesothelioma. Scientists in Italy have just released some promising findings from tests of the compound apigenin on mesothelioma cells in the lab and in live mice. What is Apigenin? Apigenin is a plant pigment that is part of a larger group of chemicals … Continue reading Chamomile Tea May Hold the Secret to Longer Mesothelioma Survival »

New Mesothelioma Study: Asbestos Fiber Burden Does Not Decline With Time

Mesothelioma has one of the longest latency periods of any disease. It is not unusual for patients to develop the asbestos cancer many decades after their last exposure to asbestos. Now, a new German study offers a more detailed explanation of why that is. Although the body is adept at ridding itself of many kinds of toxins, when asbestos fibers are inhaled or swallowed, their … Continue reading New Mesothelioma Study: Asbestos Fiber Burden Does Not Decline With Time »

Get your free copy of
“Surviving Mesothelioma” Today!